Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes
DOI10.1111/J.1541-0420.2008.01175.XzbMATH Open1172.62049OpenAlexW2096280685WikidataQ51618141 ScholiaQ51618141MaRDI QIDQ3183237FDOQ3183237
Authors: Yuan Ji, B. Nebiyou Bekele 
Publication date: 19 October 2009
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/j.1541-0420.2008.01175.x
Recommendations
- Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
- Efficient adaptive randomization and stopping rules in multi-arm clinical trials for testing a new treatment
- Comparison of designs for adaptive treatment strategies: Baseline vs. adaptive randomization
- Optimal and lead-in adaptive allocation for binary outcomes: a comparison of Bayesian methods
- A randomized play-the-winner design for multi-arm clinical trials
Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)
Cites Work
- The Calculation of Posterior Distributions by Data Augmentation
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Bivariate Survival Models Induced by Frailties
- Multivariate Generalizations of the Proportional Hazards Model
- A Continuous Bivariate Exponential Extension
- Response-Adaptive Randomization for Survival Trials: The Parametric Approach
- Monitoring the rates of composite events with censored data in phase II clinical trials
- Adaptive decision making in a lymphocyte infusion trial
Cited In (1)
This page was built for publication: Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3183237)
